National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Lapatinib (Tyverb®)

Cost-effectiveness of Lapatinib (Tyverb®) for the treatment of women with previously treated advanced or metastatic HER2 positive breast cancer.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
 December January 2008 Reimbursement recommended

Lapatinib could be considered cost-effective in Ireland. However in view of the uncertainty surrounding the ICER, we (NCPE) suggest conditional reimbursement under the High Tech Drugs scheme.

Lapatinib (Tyverb) summary